Current State of Cell Therapies for Genitourinary Malignancies

Alkhouli, Mohammed A.; Bazargan, Sarah; Pilon‐Thomas, Shari; Poch, Michael; Chahoud, Jad

doi:10.1097/ppo.0000000000000604

Cited by 9 publications

(6 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In einer Studie wurden 28 Kulturen von TIL aus PCa erfolgreich extrahiert und in vitro expandiert. Die Analyse zeigte die Expression von Chemokinrezeptoren nach der Expansion [25, 152]. Die Ergebnisse dieser Studien sind vielversprechend.…”

Section: Impfstoffbasierte Immuntherapieunclassified

Stand der Forschung und neue therapeutische Perspektiven in der Immuntherapie des Prostatakarzinoms

Maselli¹,

Giuliani²,

Laface³

et al. 2023

Kompass Onkol

View full text Add to dashboard Cite

Das Prostatakarzinom ist die häufigste Art von Tumor bei Männern. Im Frühstadium der Erkrankung ist es empfindlich gegenüber einer Androgenentzugstherapie. Bei Patienten mit metastasiertem kastrationssensitivem Prostatakarzinom (mHSPC) haben Chemotherapie und Androgenrezeptortherapien der zweiten Generation zu einer Verlängerung der Überlebenszeit geführt. Trotz der Fortschritte bei der Behandlung des mHSPC ist eine Kastrationsresistenz unvermeidlich, und viele Patienten entwickeln eine metastasierende kastrationsresistente Erkrankung (mCRPC). In den letzten Jahrzehnten hat die Immuntherapie die onkologische Landschaft dramatisch verändert und die Überlebensraten bei vielen Krebsarten erhöht. Allerdings hat die Immuntherapie beim Prostatakarzinom noch nicht die bahnbrechenden Ergebnisse gebracht, die sie bei anderen Tumorarten erzielt hat. Die Erforschung neuer Behandlungsmöglichkeiten ist für Patienten mit mCRPC aufgrund der schlechten Prognose sehr wichtig. In dieser Übersichtsarbeit konzentrieren wir uns auf die Gründe für die scheinbare intrinsische Resistenz des Prostatakarzinoms gegenüber der Immuntherapie, die Möglichkeiten zur Überwindung dieser Resistenz sowie die klinische Evidenz und auf neue therapeutische Perspektiven für die Immuntherapie des Prostatakarzinoms mit einem Blick in die Zukunft.

show abstract

Section: Impfstoffbasierte Immuntherapieunclassified

Stand der Forschung und neue therapeutische Perspektiven in der Immuntherapie des Prostatakarzinoms

Maselli¹,

Giuliani²,

Laface³

et al. 2023

Kompass Onkol

View full text Add to dashboard Cite

show abstract

“…In one study, 28 cultures of TILs resulting from PCa were successfully extracted and expanded in vitro. The analysis revealed the expression of chemokine receptors after expansion [ 25 , 152 ]. The results of these studies are promising, but CAR-T cell therapy and TILs still face many challenges because the TME in PCa is immunosuppressive and it limits the efficacy of adoptive immunotherapy.…”

Section: Adoptive Immune Cell Immunotherapymentioning

confidence: 99%

Immunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives

Maselli¹,

Giuliani

Laface³

et al. 2023

Current Oncology

View full text Add to dashboard Cite

Prostate cancer (PC) is the most common type of tumor in men. In the early stage of the disease, it is sensitive to androgen deprivation therapy. In patients with metastatic castration-sensitive prostate cancer (mHSPC), chemotherapy and second-generation androgen receptor therapy have led to increased survival. However, despite advances in the management of mHSPC, castration resistance is unavoidable and many patients develop metastatic castration-resistant disease (mCRPC). In the past few decades, immunotherapy has dramatically changed the oncology landscape and has increased the survival rate of many types of cancer. However, immunotherapy in prostate cancer has not yet given the revolutionary results it has in other types of tumors. Research into new treatments is very important for patients with mCRPC because of its poor prognosis. In this review, we focus on the reasons for the apparent intrinsic resistance of prostate cancer to immunotherapy, the possibilities for overcoming this resistance, and the clinical evidence and new therapeutic perspectives regarding immunotherapy in prostate cancer with a look toward the future.

show abstract

“…When these modified immune cells recognize the tumor expressed antigen, an immune response is initiated that causes the immune system to fight the tumor 33,34 . A recent review highlighted active clinical trials involving CAR therapy and other cellular therapies in urogenital malignancies 35 .…”

Section: Chimeric Antigen Receptor (Car) Therapymentioning

confidence: 99%

Molecularly Targeted Therapy for Urothelial Cancers

Jana,

Rischall,

Gibson

2023

MRAJ

View full text Add to dashboard Cite

Urothelial carcinoma therapy is a rapidly evolving and expanding field. Traditional cytotoxic chemotherapy regimens have not produced optimal long-term outcomes, and many urothelial cancer patients have comorbidities that disqualify them as chemotherapy candidates. In recent years, a plethora of novel therapeutic agents that target diverse molecular pathways has emerged as alternative treatment modalities for not only metastatic urothelial carcinoma, but also for muscle-invasive bladder cancer and non-muscle invasive bladder cancer in adjuvant and definitive settings. This review paper aims to discuss the various categories of therapeutic agents for these different types of urothelial cancer, discussing immunotherapy, antibody-drug conjugates, kinase inhibitors, CAR-T cell therapy, peptide vaccination, and other drugs targeting pathways such as angiogenesis, DNA synthesis, mTOR/PI3K/AKT, and EGFR/HER-2.

show abstract

Current State of Cell Therapies for Genitourinary Malignancies

Cited by 9 publications

References 79 publications

Stand der Forschung und neue therapeutische Perspektiven in der Immuntherapie des Prostatakarzinoms

Stand der Forschung und neue therapeutische Perspektiven in der Immuntherapie des Prostatakarzinoms

Immunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives

Molecularly Targeted Therapy for Urothelial Cancers

Contact Info

Product

Resources

About